Ohio State Navbar

Directory

William Blum, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-9869

Email: blum.51@osu.edu

 

Current OSU Appointments

Associate Professor, Hematology

Physician, FGP-Hematology

 

Certifications

2001 - present Board Certification in Internal Medicine: American Board of Internal Medicine
2003 - present Medical License: State Medical Board of Ohio
2004 - present Board Certification in Medical Oncology: American Board of Internal Medicine
2004 - present Board Certification in Hematology: American Board of Internal Medicine
 

Chapters in Books

Blum W, Picus J. "Prostate Cancer." In Govindan R, ed.. 383-393. Philadelphia, PA: Lippincott, Williams, and Wilkins, January 2002.

 

Conferences

Omotoso,O; Khoury,H; Adkins,D; Blum,W; Iregui,M; Westervelt,P; Vij,R; Brown,R; Goodnough,L; DiPersio,J. "Outcomes of stem cell transplant recipients requiring mechanical ventilation and cared for in the bone marrow transplant unit.." In BLOOD. (November 2001). 350B-350B.

Khoury,H; Adkins,D; Pence,H; Shenoy,S; Blum,W; Westervelt,P; Vij,R; Brown,R; Goodnough,L; DiPersio,J. "Hydroxychloroquine for prevention of acute GVHD in unrelated donor (URD) transplantation: Effect on chronic GVHD and long-term survival.." In BLOOD. (November 2001). 368B-368B.

Girgis,M; Hallemeier,C; Brown,R; Khoury,H; Zehnbauer,B; Goodnough,L; Westervelt,P; Vij,R; Blum,W; Lin,H,S; DiPersio,J; Adkins,D. "Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) results in reduced non-relapse mortality (NRM) in comparison to standard TBI-based regimens.." In BLOOD. (November 2001). 671A-671A.

Brown,R,A; Adkins,D,R; Khoury,H; Westervelt,P; Goodnough,L; Vij,R; Blum,W; DiPersio,J,F. "Mobilization of allogeneic PBSC with GM-CSF instead of G-CSF is associated with a reduced risk of acute graft-vs-host disease (GVHD).." In BLOOD. (November 2001). 737A-737A.

Shenoy,S; Hayashi,R; Goodnough,L; Khoury,H; Brown,R; Vij,R; Blum,W; DiPersio,J; Adkins,D. "Sustained improvement in post transplant NK cell function following donor derived G-CSF mobilized granulocyte transfusion in recipients of allogeneic peripheral blood stem cell transplants (SCT): Can this impact survival?." In BLOOD. (November 2001). 59A-59A.

Girgis,M; Brown,R,A; Khoury,H; Hallemeier,C; Zehnbauer,B; GOODNOUGH,L,T; Westervelt,P; Vij,R; Blum,W; Lin,H,S; DiPersio,J,F; Adkins,D,R. "Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplant (BMT) results in consistent donor cell engraftment without fatal regimen-related toxicity (RROT).." In BLOOD. (November 2001). 478A-479A.

Blum,W; Hallem,C; Vij,R; Shenoy,S; Goodnough,L; Brown,R; Khoury,H; Westervelt,P; DiPersio,J; Adkins,D. "Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: Long-term follow-up.." In BLOOD. (November 2001). 58A-58A.

Blum,W; Brown,R,A; Khoury,H; Lin,H,S; Vij,R; Oza,Y; Schultz,P; Rearden,T; Willis,R; Naughton,M; GOODNOUGH,L,T; Westervelt,P; DiPersio,J,F; Adkins,D,R. "Primary amyloidosis (AL) patients with significant organ dysfunction treated with conventional chemotherapy followed by single-dose total body irradiation (TBI) and autologous peripheral blood stem cell transplant (PBSC) the, IFN-alpha maintenance: Tolerance and efficacy.." In BLOOD. (November 2001). 684A-684A.

Devine,S,M; Adkins,D,R; Khoury,H; Vij,R; GOODNOUGH,L,T; Graubert,T; Tomasson,M; Blum,W; DiPersio,J,F; Brown,R,A. "Mobilization of donors with GM-CSF plus G-CSF or GM-CSF alone results in significantly different graft composition compared to G-CSF alone.." In BLOOD. (November 2002). 825A-825A.

Devine,S,M; Adkins,D,R; Khoury,H; Vij,R; GOODNOUGH,L,T; Graubert,T; Tomasson,M; Blum,W; DiPersio,J,F; Brown,R,A. "Impact of GM-CSF mobilization on the composition of donor allografts and the risk of acute GVHD following HLA-matched hematopoietic cell transplantation.." In BLOOD. (November 2002). 175A-175A.

Blum,W; Girgis,M; Hallemeier,C; Vij,R; Lin,H,S; Khoury,H; GOODNOUGH,L,T; Devine,S; DiPersio,J; Brown,R; Adkins,D. "Outcomes for patients with non-Hodgkin's lymphoma following donor transplantation using low dose, single exposure total body irradiation and cyclophosphamide conditioning: A single institution experience.." In BLOOD. (November 2002). 427A-427A.

Hallemeier,C; Girgis,M; Blum,W; Brown,R; Lin,H,S; Khoury,H; GOODNOUGH,L,T; Vij,R; Devine,S; Wehde,M; Postma,S; DiPersio,J; Adkins,D. "Low-dose (550 cGy), single-exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) for patients with acute myelogenous leukemia (AML) in complete remission (CR) results in reduced non-relapse mortality (NRM) and improved survival in comparison to standard TBI regimens.." In BLOOD. (November 2002). 636A-637A.

Girgis,M; Hallemeier,C; Blum,W; Brown,R; Lin,H,S; Khoury,H; GOODNOUGH,L,T; Vij,R; Devine,S; Wehde,M; Postma,S; DiPersio,J; Adkins,D. "Low-dose (556 cGy), single-exposure total body irradiation (TBI) with cyclophosphamide as conditioning for 99 patients undergoing unrelated donor (URD) bone marrow transplantation (BMT) results in a graft failure rate (7.1%) comparable to that observed with standard TBI-based regimens.." In BLOOD. (November 2002). 619A-620A.

Copelan,E; Penza,S; Lin,T; Farag,S; Blum,W; Elder,P; Ezzone,S; Avalos,B. "Matched unrelated transplantation in older individuals.." In BLOOD. (November 2003). 480B-480B.

Blum,W,G; Bolwell,B,J; Farag,S,S; Lin,T,S; Avalos,B,R; Penza,S,L; Marcucci,G; Byrd,J,C; Kalaycio,M,E; Sobecks,R,M; Pohlman,B; Brown,S; Elder,P,J; Copelan,E,A. "Only those refractory AML patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation.." In BLOOD. (November 2003). 488A-488A.

Hallemeier,C; Girgis,M; Khoury,H; Devine,S; Blum,W; Vij,R; Lin,H,S; DiPersio,J; Adkins,D. "Similar outcomes in patients >= 50 years old and patients < 50 years old undergoing unrelated donor bone marrow transplantation following reduced intensity conditioning with single exposure (550 cGy) total body irradiation and cyclophosphamide.." In BLOOD. (November 2003). 484A-484A.

Hallemeier,C; Girgis,M; Khoury,H; Devine,S; Blum,W; Vij,R; Lin,H,S; DiPersio,J; Adkins,D. "Allogeneic stem cell transplantation for 45 patients with myelodysplastic syndrome conditioned with an intermediate-intensity regimen of single exposure 550 cGy total body irradiation and cyclophosphamide.." In BLOOD. (November 2003). 467A-467A.

Blum,W; Mrozek,K; Ruppert,A,S; Carroll,A,J; Rao,K,W; Pettenati,M,J; Vardiman,J,W; Larson,R,A; Bloomfield,C,D. "Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461.." In JOURNAL OF CLINICAL ONCOLOGY. (July 2004). 568S-568S.

Marcucci,G; Stock,W; Dai,G; Liu,S; Klisovic,R; Klisovic,M,I; Sher,D; Huynh,L; FRANKEL,S; Blum,W; Larson,R,A; Grever,M,R; Byrd,J,C; Chan,K,K. "Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeoid leukemia (AML).." In BLOOD. (November 2004). 331A-331A.

Hoerr,A,L; Gao,F; Hidalgo,J; Tiwari,D; Blum,K,A; Mathews,V; Adkins,D,R; Blum,W; Devine,S; Vij,R; GOODNOUGH,L,T; DiPersio,J,F; Khoury,H,J. "Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma." In JOURNAL OF CLINICAL ONCOLOGY. (November 2004). 4561-4566.

Copelan,E,A; Penza,S; Lin,T; Blum,W; Farag,S; Elder,P; Avalos,B. "Association between regimen related toxicity and acute-graft-versus-host disease.." In BLOOD. (November 2004). 337B-337B.

Blum,W; Penza,S; Farag,S; Avalos,B; Marcucci,G; Lin,T; Byrd,J,C; Elder,P; Copelan,E,A. "Incidence of extramedullary relapse of acute myeloid leukemia following transplantation with busulfan-based conditioning regimens.." In BLOOD. (November 2004). 364B-364B.

Blum,W; Blum,K,A; Kefauver,C; Moran,M; Chan,K; Byrd,J,C; Cataland,S; Grever,M,R; Marcucci,G. "Decitabine-induced differentiation syndrome in a patient with acute myeloid leukemia: A case report.." In BLOOD. (November 2004). 215B-216B.

Benson,D,M; Elder,P,J; Lin,T; Blum,W; Penza,S; Avalos,B; Byrd,J,C; Copelan,E; Farag,S,S. "Single institution experience with two high-dose chemotherapy (HDC) conditioning regimens prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM)." In BLOOD. (November 2004). 388B-389B.

Blum,W; Bruner-Klisovic,R; Liu,S,J; Byrd,J,C; Liu,Z,F; Chan,K,K; Kefauver,C; Huynh,L; Grever,M,R; Marcucci,G. "Phase I study of low dose decitabine in patients with acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity.." In BLOOD. (November 2005). 529A-529A.

Blum,W; Mrozek,K; Maharry,K; Raimondi,S,C; Carroll,A,J; Larson,R,A; Rowley,J,D; Bloomfield,C,D. "Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23.." In JOURNAL OF CLINICAL ONCOLOGY. (June 2005). 572S-572S.

Klisovic,R,B; Blum,W; Wei,X; Liu,S; Kefauver,C; Huynh,L; Zwiebel,J,A; Byrd,J,C; Grever,M,R; Marcucci,G. "A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamic (PD) and clinical results." In BLOOD. (November 2005). 782A-783A.

Marcucci,G; Klisovic,R,B; Wei,W; Liu,S; Paschka,P; Huynh,L; Zwiebel,J,A; Byrd,J,C; Grever,M,R; Chan,K; Blum,W. "A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML).." In JOURNAL OF CLINICAL ONCOLOGY. (June 2006). 352S-352S.

Klisovic,R,B; Blum,W; Hackanson,B; Kefauver,C; Liu,S; Liu,Z; Chan,K,K; Plass,C; Grever,M,R; Byrd,J,C; Marcucci,G. "Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response.." In JOURNAL OF CLINICAL ONCOLOGY. (June 2006). 340S-340S.

Blum,W; Klisovic,R,B; Kefauver,C; Johnson,A; Phelps,M; Dalton,J,T; Lucas,D; Colevas,A,D; Grever,M,R; Marcucci,G; Byrd,J,C. "Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics.." In JOURNAL OF CLINICAL ONCOLOGY. (June 2006). 353S-353S.

Blum,William; Marcucci,Guido; Devine,Hollie; Klisovic,Rebecca. "Imatinib mesylate-induced complete cytogenetic response in acute myeloid leukemia with t(5;12)(q33;p13).." In BLOOD. (November 2006). 181B-181B.

Blum,William; Klisovic,Rebecca,B; Kefauver,Cheryl; Johnson,Amy; Phelps,Mitch; Dalton,James,T; Lucas,David; Huynh,Le,Nguyen; Liu,Shujun; Grever,Michael,R; Colevas,A,D; Marcucci,Guido; Byrd,John,C. "Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).." In BLOOD. (November 2006). 224B-224B.

Ali,Naeem,A; O'Brien,James,M; Blum,William; Klisovic,Rebecca,B; Marcucci,Guido; Phillips,Gary; Marsh,Clay,B; Lemeshow,Stanley; Byrd,John,C; Grever,Michael,R. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.." In BLOOD. (November 2006). 476B-476B.

Ali,Naeem,A; O'Brien,James,M; Blum,William; Byrd,John,C; Klisovic,Rebecca,B; Marcucci,Guido; Phillips,Gary; Marsh,Clay,B. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." In CANCER. (July 2007). 96-102.

Blum,William; Klisovic,Rebecca,B; Hackanson,Bjoern; Liu,Zhongfa; Liu,Shujun; Devine,Hollie; Vukosavljevic,Tamara; Huynh,LeNguyen; Lozanski,Gerard; Kefauver,Cheryl; Plass,Christoph; Devine,Steven,M; Heerema,Nyla,A; Murgo,Anthony; Chan,Kenneth,K; Grever,Michael,R; Byrd,John,C; Marcucci,Guido. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." In JOURNAL OF CLINICAL ONCOLOGY. (September 2007). 3884-3891.

Garzon,Ramiro; Liu,Shujun; Fabbri,Muller; Liu,Zhongfa; Pang,Jiuxia; Muthusamy,Natarajan; Blum,William; Chan,Kenneth; Byrd,John,C; Croce,Carlo,M; Marcucci,Guido. "MicroRNA (miRNA)-29b targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 genes in acute myeloid leukemia (AML).." In BLOOD. (November 2007). 220A-220A.

Wetzler,Meir; Stock,Wendy; Donohue,Kathleen,A; Owzar,Kouros; Sher,Doric,A; Hoke,Eva,E; McCarty,John,M; Blum,William,G; Powell,Bayard,L; Bloomfield,Clara,D; Linker,Charles,A; Larson,Richard,A. "Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001." In BLOOD. (November 2007). 843A-844A.

Blum,William; Marcucci,Guido. "New approaches in acute myeloid leukemia." In BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. (March 2008). 29-41.

Blum,W,G; Andritsos,L,A; Johnson,A,J; Klisovic,R,B; Kefauver,C; Devine,S,M; Marcucci,G; Byrd,J,C. "Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose." In JOURNAL OF CLINICAL ONCOLOGY. (May 2008). unknown-.

Blum,William; Klisovic,Rebecca; Liu,Shujun; Garzon,Ramiro; Kefauver,Cheryl; Liu,Zhongfa; Mickle,Jon; Devine,Hollie; Devine,Steve; Grever,Michael,R; Chan,Kenneth,K; Villalona-Calero,Miguel; Byrd,John,C; Marcucci,Guido. "Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age >= 60) with Previously Untreated Acute Myeloid Leukemia (AML)." In BLOOD. (November 2008). 1016-1016.

Benson,Don; Andritsos,Leslie; Hamadani,Mehdi; Lin,Thomas; Flynn,Joseph; Jones,Jeffrey; Blum,William; Elder,Patrick; Lozanski,Gerard; Byrd,John; Devine,Steven. "Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation.." In BLOOD. (November 2008). 1133-1134.

Andritsos,Leslie; Hamadani,Mehdi; Heerema,Nyla,A; Benson,Don; Hofmeister,Craig,C; Blum,William; Flynn,Joseph; Jones,Jeffrey,Alan; Elder,Patrick; Lin,Thomas,S; Lozanski,Gerard; Byrd,John,C; Devine,Steven. "Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)." In BLOOD. (November 2008). 756-757.

Hamadani,M; Phillips,G; Elder,P; Yansak,B; Blum,W; Penza,S; Lin,T,S; Farag,S,S; Devine,S,M. "PHASE-II STUDY OF INFLIXIMAB FOR THE PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2008). 130-131.

Chen,Ping; Blum,William; Aimiuwu,Josephine; Upadhyayula,Vijayasarathi; Liu,Zhongfa; Liu,Shujun; Pang,Jiuxia; Walker,Alison; Klisovic,Rebecca,B; Garzon,Ramiro; Grever,Michael,R; Villalona-Calero,Miguel; Byrd,John,C; Chan,Kenneth,K; Marcucci,Guido. "Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." In BLOOD. (November 2009). 1454-1455.

Chandler,Jason,C; Klisovic,Rebecca,B; Phelps,Mitch,A; Walker,Alison; Garzon,Ramiro; Yang,Xiaoxia; Schaaf,Larry; Schwind,Sebastian; Becker,Heiko; Liu,Shujun; Hickey,Chris; Kefauver,Cheryl; Mickle,Jon; Devine,Steven,M; Grever,Michael,R; Byrd,John,C; Marcucci,Guido; Blum,William. "Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia." In BLOOD. (November 2009). 346-347.

Blum,William; Klisovic,Rebecca,B; Walker,Alison; Garzon,Ramiro; Liu,Shujun; Schaaf,Larry,J; Humphries,Kristina; Grever,Michael,R; Devine,Steven,M; Byrd,John,C; Marcucci,Guido. "Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)." In BLOOD. (November 2009). 815-816.

Metzeler,K; Maharry,K; Margeson,D; Curfman,J; Becker,H; Radmacher,M; Mrozek,K; Holland,K; Whitman,S; Wu,Y; Schwind,S; Blum,W; Powell,B; Carter,T; Baer,M; Carroll,A; Kolitz,J; Caligiuri,M; Larson,R; Marcucci,G; Bloomfield,C. "TET2 MUTATIONS OCCUR IN OVER 20% OF ADULTS WITH DE NOVO CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA, AND THEIR PREVALENCE INCREASES WITH AGE: A CANCER AND LEUKEMIA GROUP B STUDY." In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. (June 2010). 12-13.

Blum,William; Donohue,Kate; Marcucci,Guido; DeAngelo,Daniel,J; Uy,Geoffrey,L; Powell,Bayard,L; Stock,Wendy; Baer,Maria; Kolitz,Jonathan,E; Wetzler,Meir; Hoke,Eva; Moser,Barry,K; Larson,Richard,A. "Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study." In BLOOD. (November 2010). 898-899.

Blum,William; Klisovic,Rebecca,B; Garzon,Ramiro; Walker,Alison; Schwind,Sebastian; Liu,Shujun; Schaaf,Larry; Garr,Celia; Devine,Steven,M; Greyer,Michael,R; Byrd,John,C; Marcucci,Guido. "Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)." In BLOOD. (November 2010). 1349-1349.

Khoury,H,Jean; Collins,Robert,H; Blum,William; Maness,Lori; Stiff,Patrick; Kelsey,Stephen,M; Reddy,Anita; Smith,Jennifer,A; DiPersio,John,F. "Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with, Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)." In BLOOD. (November 2010). 904-904.

Mendler,Jason,H; Maharry,Kati; Radmacher,Michael,D; Mrozek,Krzysztof; Kohlschmidt,Jessica; Nicolet,Deedra; Becker,Heiko; Metzeler,Klaus,H; Schwind,Sebastian; Whitman,Susan,P; Blum,William; Powell,Bayard,L; Kolitz,Jonathan,E; Carter,Thomas,H; Wetzler,Meir; Moore,Joseph,O; Carroll,Andrew,J; Baer,Maria,R; Larson,Richard,A; Caligiuri,Michael,A; Marcucci,Guido; Bloomfield,Clara,D. "Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures." In BLOOD. (November 2011). 1476-1477.

Edwards,Colin,G; Maharry,Kati; Mrozek,Krzysztof; Schwind,Sebastian; Paschka,Peter; Nicolet,Deedra; Kohlschmidt,Jessica; Prior,Thomas,W; Wu,Yue-Zhong; Kolitz,Jonathan,E; Blum,William; Pettenati,Mark,J; Dal Cin,Paola; Carroll,Andrew,J; Caligiuri,Michael,A; Larson,Richard,A; Marcucci,Guido; Bloomfield,Clara,D. "Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)." In BLOOD. (November 2011). 1077-1077.

Walker,Alison,R; Metzeler,Klaus,H; Geyer,Susan; Becker,Heiko; Schwind,Sebastian; Whitman,Susan,P; Curfman,John; Wu,Yue-Zhong; Perrotti,Danilo; Klisovic,Rebecca,B; Garzon,Ramiro; Blum,William; Marcucci,Guido. "Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)." In BLOOD. (November 2011). 430-430.

Hamadani,M; Craig,M; Abraham,J; Tse,W; Cumpston,A; Gibson,L,F; Remick,S,C; Leadmon,S; Elder,P; Hofmeister,C; Penza,S; Andritsos,L; Blum,W; Benson,D,M; Devine,S,M. "HIGHER BUSULFAN DOSE INTENSITY DOES NOT IMPROVE OUTCOMES OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) FOLLOWING FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED TOXICITY CONDITIONING (RTC)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2011). S306-S306.

Hamadani,Mehdi; Craig,Michael; Remick,Scot; Gibson,Laura; Petros,William; Abraham,Jame; Cumpston,Aaron; Bunner,Pamela; Basu,Soumit; Tse,William; Hennelly,Carrie; Vasu,Sumithira; Klisovic,Rebecca,B; Blum,William; Jaglowski,Samantha,M; Benson,Don,M; Andritsos,Leslie,A; Penza,Sam; Hofmeister,Craig,C; Geyer,Susan; Devine,Steven,M; Efebera,Yvonne,A. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In BLOOD. (November 2012). unknown-.

Blum,William; Sanford,Ben; Klisovic,Rebecca,B; DeAngelo,Daniel,J; Uy,Geoffrey; Powell,Bayard,L; Stock,Wendy; Baer,Maria,R; Kolitz,Jonathan,E; Wetzler,Meir; Hoke,Eva; Bloomfield,Clara,D; Geyer,Susan; Marcucci,Guido; Stone,Richard,M; Larson,Richard,A. "Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)." In BLOOD. (November 2012). unknown-.

Blum,William; Klisovic,Rebecca,B; Walker,Alison; Schwind,Sebastian; Jiang,Yao; Wang,Jiang; Phelps,Mitch; Geyer,Susan; Devine,Steven,M; Walsh,Kathy; Vasu,Sumithira; Curfman,John,P; Schaaf,Larry; Garr,Celia; Kefauver,Cheryl; Byrd,John,C; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.." In BLOOD. (November 2012). unknown-.

Blum,William; Klisovic,Rebecca,B; Walker,Alison; Schwind,Sebastian; Jiang,Yao; Wang,Jiang; Phelps,Mitch; Geyer,Susan; Devine,Steven,M; Walsh,Kathy; Vasu,Sumithira; Curfman,John,P; Schaaf,Larry; Garr,Celia; Kefauver,Cheryl; Byrd,John,C; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine." In BLOOD. (November 2012). unknown-.

Wang,Hongyan; Chen,Ping; Wang,Jiang; Santhanam,Ramasamy; Aimiuwu,Josephine; Uv,Vijayasaradhi; Liu,Zhongfa; Schwind,Sebastian; Mims,Alice,S; Klisovic,Rebecca,B; Walker,Alison; Grever,Michael,R; Villalona-Calero,Miguel; Byrd,John,C; Garzon,Ramiro; Blum,William; Chan,Kenneth,K; Marcucci,Guido. "Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)." In BLOOD. (November 2012). unknown-.

Klisovic,Rebecca,B; Wang,Hongyan; Walker,Alison; Walsh,Katherine; Vasu,Sumithira; Garzon,Ramiro; Devine,Steven,M; Wang,Jiang; Garr,Celia; Norris,Adam; Byrd,John,C; Grever,Michael,R; Blum,William; Chan,Kenneth,K; Marcucci,Guido. "Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results." In BLOOD. (November 2012). unknown-.

Jaglowski,Samantha,M; Vasu,Sumithira; Geyer,Susan; Bingman,Anissa; Elder,Patrick; Yu,Jianhua; Blum,William; Klisovic,Rebecca,B; Penza,Sam; Efebera,Yvonne,A; Hofmeister,Craig,C; Benson,Don,M; Muthusamy,Natarajan; Devine,Steven,M; Andritsos,Leslie,A; Lozanski,Gerard. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In BLOOD. (November 2012). unknown-.

Attar,Eyal,C; Johnson,Jeffrey,L; Amrein,Philip,C; Lozanski,Gerard; Wadleigh,Martha; DeAngelo,Daniel,J; Kolitz,Jonathan,E; Powell,Bayard,L; Voorhees,Peter,Michael; Wang,Eunice,S; Blum,William,G; Marcucci,Guido; Bloomfield,Clara,D; Moser,Barry,K; Stone,Richard,M; Larson,Richard,A. "A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.." In JOURNAL OF CLINICAL ONCOLOGY. (May 2012). 923-929.

Rodriguez,Benjamin,AT; Frankhouser,David; Murphy,Mark; Trimarchi,Michael; Tam,Hok-Hei; Curfman,John; Huang,Rita; Chan,Michael,WY; Lai,Hung-Cheng; Parikh,Deval; Ball,Bryan; Schwind,Sebastian; Blum,William; Marcucci,Guido; Yan,Pearlly; Bundschuh,Ralf. "Methods for high-throughput MethylCap-Seq data analysis." In BMC GENOMICS. (October 2012). S14-.

Wetzler,Meir; Watson,Dorothy; Stock,Wendy; Owzar,Kouros; Koval,Gregory; Hoke,Eva; McCarty,John,M; Blum,William; Powell,Bayard,L; Marcucci,Guido; Bloomfield,Clara,D; Linker,Charles; Larson,Richard,A. "Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)." In BLOOD. (November 2012). 816-.

Salem,Galena; Ruppert,Amy,S; Elder,Patrick; Hofmeister,Craig,C; Benson,Don,M; Penza,Sam; Andritsos,Leslie,A; Klisovic,Rebecca; Vasu,Sumithira; Blum,William; Devine,Steven,M; Jaglowski,Samantha; Efebera,Yvonne. "Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S304-S305.

Cohen,Jonathon,B; McBride,Ali; Geyer,Susan; Bingman,Anissa; Elder,Patrick; Blum,William; Klisovic,Rebecca; Penza,Sam; Andritsos,Leslie,A; Benson,Don,M; Efebera,Yvonne; Hofineister,Craig,C; Garzon,Ramiro; Marcucci,Guido; Devine,Steven,M. "Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S320-S321.

Pandit,Akshata; Wei,Lai; Elder,Patrick; Falk,William; Sell,Megan; Hofmeister,Craig,C; Benson,Don,M; Penza,Sam; Andritsos,Leslie,A; Klisovic,Rebecca; Vasu,Sumithira; Blum,William; Devine,Steven,M; Jaglowski,Samantha; Efebera,Yvonne. "Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S186-S186.

Efebera,Yvonne; Geyer,Susan; Bingman,Anissa; Kitzler,Rhonda; Elder,Patrick; Hennelly,Carrie; Andritsos,Leslie,A; Jaglowski,Samantha; Blum,William; Klisovic,Rebecca; Penza,Sam; Vasu,Sumithira; Hofmeister,Craig,C; Benson,Don,M; Devine,Steven,M; Lozanski,Gerard. "Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S202-S202.

Jiang,Y; Wang,J; Walker,A; Li,X; Drake,A; Schaaf,L; Byrd,J; Marcucci,G; Grever,M; Blum,W; Phelps,M. "LENALIDOMIDE PHARMACOKINETICS IN COMBINATION WITH IDARUBION AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.." In CLINICAL PHARMACOLOGY & THERAPEUTICS. (February 2013). S66-S67.

 

Degrees

1993 B.S., University of Notre Dame

1997 M.D., Medical College of Georgia

 

Editorial Activities

2003 British Journal of Hematology
2004 Annals of Hematology
2006 - present Cancer Chemotherapy and Pharmacotherapy
2006 - 2009 Haematologica
2007 - present Italian Association of Cancer Research
2007 - present Scandinavian Journal of Infectious Disease
2007 - present American Journal of Hematology
2009 - present Leukemia and Lymphoma
2010 - present Blood, Leukemia
 

Honors

1991 Summer Research Student Award, lab of Douglas Boyd.
1992 Summer Research Student Award, lab of David Harrison.
1994 - 1995 School of Medicine Scholarship.
1995 Academic commendation Letter.
1995 CD Whitaker Scholarship.
1995 Award for Excellence in Scholarship.
1996 Alpha Omega Alpha.
2000 Jefferson Cup for Excellence in Resident Research.
2003 Selected Participant, AACR/ASCO Workshop "Methods of Clinical Cancer Research".
2003 - 2009 Service Award in the College of Medicine Educational Programs.
2004 Selected Participant, ASH Clinical Research Training Institute (CRTI).
2010 Chair and invited speaker, Education session for myelodsplastic syndromes. American Society of Hematology.
2011 - present Best Doctors. Best Doctors in America.
2011 Invited Speaker. American Society of Hematology.
2013 Invited Consultant. American Society of Hematology.
2014 Invited Speaker. American Society of Clinical Oncology.
 

Journal Articles

Blum W. "Advances in Non-transplant therapy for Chronic Myelogenous Leukemia." The Fellow Reporter. Vol. 7, no. 4. (January 2002.): 44-48.

Blum W, Brown R, lin H-S, Zehnbaeur B, Khoury H, Goodnough LT, Westervelt P, Vij R, Dipersio J, Adkins D. "Low dose (550cGy), single exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related donor peripheral blood stem cells with low treatment-related organ mortality and fatal organ toxicity.." Biology of Blood and Marrow Transplantation. Vol. 8, no. 11. (January 2002.): 608-618.

Vij, Ravi; DiPersio, John, F; Venkatraman, Partha; Trinkaus, Kathryn; Goodnough, Lawrence, T; Brown, Randy, A; Khoury, Hanna, J; Devine, Steven, M; Oza, Aarti; Shenoy, Shalini; Blum, William; Adkins, Douglas. "Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation.." Blood. Vol. 101, no. 5. (January 2003.): 2067-2069.

Vij, R; Khoury, H; Brown, R; Goodnough, L, T; Devine, S, M; Blum, W; Adkins, D; DiPersio, J F. "Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation.." Bone marrow transplantation. Vol. 32, no. 7. (January 2003.): 703-707.

Blum W, Khoury H, Lin H-S, Vij R, Goodnough LT, Devine S, Dipersio J, Adkins D. "Primary (AL) Amyloidosis Patients with Significant Organ Dysfunction Tolerate Autologous Transplantation following Conditioning with Single Dose (550cGy), Single exposure total body irradiation Alone: A Feasibility Study." Biology of Blood and Marrow Transplantation. Vol. 9, no. 6. (January 2003.): 397-404.

Devine, Steven, M; Adkins, Douglas, R; Khoury, Hanna; Brown, Randy, A; Vij, Ravi;Blum, William; DiPersio, John F. "Recent advances in allogeneic hematopoietic stem-cell transplantation.." JOURNAL OF LABORATORY AND CLINICAL MEDICINE. Vol. 141, no. 1. (January 2003.): 7-32.

Chohan, Rizwana; Vij, Ravi; Adkins, Douglas; Blum, William; Brown, Randy; Tomasson, Michael; Devine, Steven; Graubert, Timothy; Goodnough, Lawrence, T; DiPersio, John, F; Khoury, Hanna. "Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.." British journal of haematology. Vol. 123, no. 1. (January 2003.): 110-113.

Blum, William; Mrozek, Krzysztof; Ruppert, Amy S.; Carroll, Andrew J.; Rao, Kathleen W.; Pettenati, Mark J.; Anastasi, John; Larson, Richard A.; Bloomfield, Clara D.. "Adult de novo acute myeloid leukemia with t(6;1 1)(q27;q23) - Results from cancer and leukemia group B study 8461 and review of the literature." Cancer. Vol. 101, no. 6. (January 2004.): 1420-1427.

Hidalgo, J, D; Krone, R; Rich, M, W; Blum, K; Adkins, D; Fan, M-Y; Brown, R; Devine, S; Graubert, T; Blum, W; Tomasson, M; Goodnough, L, T; Vij, R; DiPersio, J; Khoury, H. "Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes.." Bone marrow transplantation. Vol. 34, no. 7. (January 2004.): 615-619.

Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, DiPersio J, Adkins D. "Outcomes of adults with actue myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants." Biology of Blood and Marrow Transplantation. Vol. 10, no. 5. (January 2004.): 310-319.

Hoerr, Amy, L; Gao, Feng; Hidalgo, Josephine; Tiwari, Divya; Blum, Kristie, A; Mathews, Vikram; Adkins, Douglas, R; Blum, William; Devine, Steven; Vij, Ravi; Goodnough, Lawrence, T; Dipersio, John, F; Khoury, Hanna J. "Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 22, no. 22. (January 2004.): 4561-6.

Marcucci, Guido; Stock, Wendy; Dai, Guowei; Klisovic, Rebecca, B; Liu, Shujun; Klisovic, Marko, I; Blum, William; Kefauver, Cheryl; Sher, Dorie, A; Green, Margaret; Moran, Mollie; Maharry, Kati; Novick, Steven; Bloomfield, Clara, D; Zwiebel, James, A; Larson, Richard, A; Grever, Michael, R; Chan, Kenneth, K; Byrd, John C. "Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 23, no. 15. (January 2005.): 3404-3411.

Girgis, Mark; Hallemeier, Chris; Blum, William; Brown, Randy; Lin, Hsiu-San; Khoury, Hanna; Goodnough, L Tim; Vij, Ravi; Devine, Steve; Wehde, Marita; Postma, Stacey; Oza, Aarti; Dipersio, John; Adkins, Douglas. "Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide.." Blood. Vol. 105, no. 8. (January 2005.): 3035-3041.

Benson DM, O'Donnell L, Krugh D, Grady T, Blum W, Williams JD, Kennedy MS, Marcucci G. "Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis." BONE MARROW TRANSPLANTATION. Vol. 36, no. 12. (January 2005.): 1111-1112.

Blum W, Marcucci G. Clin Adv Hematol Oncol. Vol. 3, no. 11. (January 2005.): 855-865, 882.

Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E. "High-dose busulfan, cyclophosphamide, and Etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia." BONE MARROW TRANSPLANTATION. Vol. 35, no. 7. (January 2005.): 653-661.

Hallemeier CL, Girgis MD, Blum W, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, Dipersio JF, Adkins DR. "Long-Term Remissions in Patients with Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia Undergoing Allogeneic Transplantation Following a Reduced Intensity Conditioning REgimen of 550 cGy Toal Body Irradiation and Cyclophosphamide." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 12, no. 7. (January 2006.): 749-757.

Blum, William; Bolwell, Brian, J; Phillips, Gary; Farag, Sherif, S; Lin, Thomas, S; Avalos, Belinda, R; Penza, Sam, L; Marcucci, Guido; Byrd, John, C; Kalaycio, Matt, E; Sobecks, Ronald, M; Pohlman, Brad; Brown, Stacey; Elder, Patrick, J; Copelan, Edward A. "High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 12, no. 1. (January 2006.): 61-67.

Wei, Xiaohui; Dai, Guowei; Marcucci, Guido; Liu, Zhongfa; Hoyt, Dale; Blum, William; Chan, Kenneth K. "A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.." Pharmaceutical research. Vol. 23, no. 6. (January 2006.): 1251-1264.

Liu, Shujun; Klisovic, Rebecca, B; Vukosavljevic, Tamara; Yu, Jianhua; Paschka, Peter; Huynh, Lenguyen; Pang, Jiuxia; Neviani, Paolo; Liu, Zhongfa; Blum, William; Chan, Kenneth, K; Perrotti, Danilo; Marcucci, Guido. "Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. Vol. 321, no. 3. (January 2007.): 953-960.

Ali, Naeem, A; O'Brien, James M Jr; Blum, William; Byrd, John, C; Klisovic, Rebecca, B; Marcucci, Guido; Phillips, Gary; Marsh, Clay, B; Lemeshow, Stanley; Grever, Michael R. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.." Cancer. Vol. 110, no. 1. (January 2007.): 96-102.

Blum, William; Klisovic, Rebecca, B; Hackanson, Bjoern; Liu, Zhongfa; Liu, Shujun; Devine, Hollie; Vukosavljevic, Tamara; Huynh, Lenguyen; Lozanski, Gerard; Kefauver, Cheryl; Plass, Christoph; Devine, Steven, M; Heerema, Nyla, A; Murgo, Anthony; Chan, Kenneth, K; Grever, Michael, R; Byrd, John, C; Marcucci, Guido. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 25, no. 25. (January 2007.): 3884-3891.

Cheng, Hao; Liu, Zhongfa; Blum, William; Byrd, John, C; Klisovic, Rebecca; Grever, Michael, R; Marcucci, Guido; Chan, Kenneth K. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. Vol. 850, no. 1-2. (January 2007.): 206-212.

Benson, Don M Jr; Elder, Patrick, J; Lin, Thomas, S; Blum, William; Penza, Sam; Avalos, Belinda; Copelan, Edward; Farag, Sherif S. "High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.." Leukemia research. Vol. 31, no. 8. (January 2007.): 1069-1075.

Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Blum, William; Perrotti, Danilo; Paschka, Peter; Klisovic, Rebecca; Byrd, John; Chan, Kenneth, K; Marcucci, Guido. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.." Nucleic acids research. Vol. 35, no. 5. (January 2007.): e31-.

Blum W, Porcu P. Seminars in Thrombosis and Hemostasis. Vol. 33, no. 4. (January 2007.): 350-354.

Trifilio, S, M; Bennett, C, L; Yarnold, P, R; McKoy, J, M; Parada, J; Mehta, J; Chamilos, G; Palella, F; Kennedy, L; Mullane, K; Tallman, M, S; Evens, A; Scheetz, M, H; Blum, W; Kontoyiannis, D P. "Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.." Bone marrow transplantation. Vol. 39, no. 7. (January 2007.): 425-429.

Hamadani, M; Benson, D M Jr; Blum, W; Garzon, R; Devine, S M. "Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease.." TRANSPLANT INFECTIOUS DISEASE. Vol. 10, no. 1. (January 2008.): 24-26.

Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. "Phase I study of GTI-2040, an antisense to ribonucleotide reductase in combination with high-dose cytarabine in patients with acute myeloid leukemia." Clin Cancer Res. Vol. 14, no. 12. (June 2008.): 3889-3895.

Klisovic, Rebecca, B; Stock, Wendy; Cataland, Spero; Klisovic, Marko, I; Liu, Shujun; Blum, William; Green, Margaret; Odenike, Olatoyosi; Godley, Lucy; Burgt, Jennifer Vanden; Van Laar, Emily; Cullen, Michael; Macleod, A Robert; Besterman, Jeffrey, M; Reid, Gregory, K; Byrd, John, C; Marcucci, Guido. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 14, no. 8. (January 2008.): 2444-2449.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-{kappa}B-dependent DNA methyltransferase activity in acute myeloid leukemia." Blood. Vol. 111, no. 4. (February 2008.): 2364-2373.

Plass C, Oakes C, Blum W, Marcucci G. Semin Oncol. Vol. 35, no. 4. (January 2008.): 378-387.

Blum W, Marcucci G. Best Practice & Research. Clinical Haematology. Vol. 21, no. 1. (January 2008.): 29-41.

Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. "Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug." JOURNAL OF CLINICAL INVESTIGATION. Vol. 118, no. 7. (July 2008.): 2427-2437.

Plass,Christoph; Oakes,Christopher; Blum,William; Marcucci,Guido. "Epigenetics in acute myeloid leukemia." SEMINARS IN ONCOLOGY. Vol. 35, no. 4. (August 2008.): 378-387.

Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC. "Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia." JOURNAL OF CLINICAL ONCOLOGY. Vol. 26, no. 29. (October 2008.): 4851-4852.

Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT. "Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma." JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. Vol. 871, no. 1. (June 2008.): 15-21.

Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. "Lenalidomide down regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lympocytic leukemia cells." Blood. Vol. 112, no. 13. (September 2008.): 5180-5189.

Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W. "Single agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13." Blood. Vol. 113, no. 5. (September 2008.): 1002-1005.

Blum W. Haematologica. Vol. 93, no. 6. (June 2008.): 801-805.

Hamadani, Mehdi; Hofmeister, Craig, C; Jansak, Buffy; Phillips, Gary; Elder, Patrick; Blum, William; Penza, Sam; Lin, Thomas, S; Klisovic, Rebecca; Marcucci, Guido; Farag, Sherif, S; Devine, Steven M. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 14, no. 7. (January 2008.): 783-789.

Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrorri D, Adnreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. "MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B adn indirectly DNMT1." Blood. Vol. 113, no. 25. (June 2009.): 6411-6418.

Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. "Improved nonrelapse mortaility and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 15, no. 11. (November 2009.): 1422-1430.

Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R, Blum W, Grever MR, Marcucci G, Chan KK. "A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels." PHARMACEUTICAL RESEARCH. Vol. 26, no. 6. (March 2009.): 1504-1515.

Hamandani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. "Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 15, no. 5. (May 2009.): 547-553.

Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Vol. 95, no. 7. (July 2010.): 1098-1105.

Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phleps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." JOURNAL OF CLINICAL ONCOLOGY. Vol. 28, no. 33. (October 2010.): 4919-4925.

Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerma NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 107, no. 16. (April 2010.): 7473-7478.

Lapalombella R, Andritsos L, Liu Q, May SE, Browining R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC. "Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a P13-kinase-dependent pathway." Blood. Vol. 115, no. 13. (April 2010.): 2619-2629.

Blum,William. "How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes." HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM. Vol. 1, (December 2010.): 314-321.

Schroeder MA, Blum W. "Evidence-based mini-review: Should patients over the ag of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia." Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. Vol. 2010, no. 2010. (January 2010.): 322-324.

Blum W. "How much? How Frequent? How long? A Clinical guide to new therapies in myelodysplastic syndromes." Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. Vol. 2010, no. 2010. (January 2010.): 314-321.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. "TET2 mutations improve the New European LeukemiaNet risk classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study." JOURNAL OF CLINICAL ONCOLOGY. Vol. 29, no. 10. (April 2011.): 1373-1381.

Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. "Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning." HEMATOLOGICAL ONCOLOGY. Vol. 29, no. 4. (February 2011.): 202-210.

Blum,William,G. "Hypomethylating agents in myelodysplastic syndromes.." Clinical advances in hematology & oncology : H&O. Vol. 9, no. 2. (February 2011.): 123-?.

Troeger,Anja; Johnson,Amy,J; Wood,Jenna; Blum,William,G; Andritsos,Leslie,A; Byrd,John,C; Williams,David,A. "RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans." BLOOD. Vol. 119, no. 20. (May 2012.): 4708-4718.

Aimiuwu,Josephine; Wang,Hongyan; Chen,Ping; Xie,Zhiliang; Wang,Jiang; Liu,Shujun; Klisovic,Rebecca; Mims,Alice; Blum,William; Marcucci,Guido; Chan,Kenneth,K. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia." BLOOD. Vol. 119, no. 22. (May 2012.): 5229-5238.

Yan,Pearlly; Frankhouser,David; Murphy,Mark; Tam,Hok-Hei; Rodriguez,Benjamin; Curfman,John; Trimarchi,Michael; Geyer,Susan; Wu,Yue-Zhong; Whitman,Susan,P; Metzeler,Klaus; Walker,Alison; Klisovic,Rebecca; Jacob,Samson; Grever,Michael,R; Byrd,John,C; Bloomfield,Clara,D; Garzon,Ramiro; Blum,William; Caligiuri,Michael,A; Bundschuh,Ralf; Marcucci,Guido. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia." BLOOD. Vol. 120, no. 12. (September 2012.): 2466-2474.

Metzeler,K,H; Walker,A; Geyer,S; Garzon,R; Klisovic,R,B; Bloomfield,C,D; Blum,W; Marcucci,G. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." LEUKEMIA. Vol. 26, no. 5. (May 2012.): 1106-1107.

Aimiuwu,Josephine; Wang,Hongyan; Chen,Ping; Xie,Zhiliang; Wang,Jiang; Liu,Shujun; Klisovic,Rebecca; Mims,Alice; Blum,William; Marcucci,Guido; Chan,Kenneth,K. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia." BLOOD. Vol. 119, no. 22. (May 2012.): 5229-5238.

Blum,William; Schwind,Sebastian; Tarighat,Somayeh,S; Geyer,Susan; Eisfeld,Ann-Kathrin; Whitman,Susan; Walker,Alison; Klisovic,Rebecca; Byrd,John,C; Santhanam,Ramasamy; Wang,Hongyan; Curfman,John,P; Devine,Steven,M; Jacob,Samson; Garr,Celia; Kefauver,Cheryl; Perrotti,Danilo; Chan,Kenneth,K; Bloomfield,Clara,D; Caligiuri,Michael,A; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.

Alvarnas,Joseph,C; Brown,Patrick,A; Aoun,Patricia; Ballen,Karen,Kuhn; Bellam,Naresh; Blum,William; Boyer,Michael,W; Carraway,Hetty,E; Coccia,Peter,F; Coutre,Steven,E; Cultrera,Jennifer; Damon,Lloyd,E; DeAngelo,Daniel,J; Douer,Dan; Frangoul,Haydar; Frankfurt,Olga; Goorha,Salil; Millenson,Michael,M; O'Brien,Susan; Petersdorf,Stephen,H; Rao,Arati,V; Terezakis,Stephanie; Uy,Geoffrey; Wetzler,Meir; Zelenetz,Andrew,D; Naganuma,Maoko; Gregory,Kristina,M. "Acute Lymphoblastic Leukemia." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vol. 10, no. 7. (July 2012.): 858-913.

Ranganathan,Parvathi; Yu,Xueyan; Na,Caroline; Santhanam,Ramasamy; Shacham,Sharon; Kauffman,Michael; Walker,Alison; Klisovic,Rebecca; Blum,William; Caligiuri,Michael; Croce,Carlo,M; Marcucci,Guido; Garzon,Ramiro. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.

Hickey,Christopher,J; Schwind,Sebastian; Radomska,Hanna,S; Dorrance,Adrienne,M; Santhanam,Ramasamy; Mishra,Anjali; Wu,Yue-Zhong; Alachkar,Houda; Maharry,Kati; Nicolet,Deedra; Mrozek,Krzysztof; Walker,Alison; Eiring,Anna,M; Whitman,Susan,P; Becker,Heiko; Perrotti,Danilo; Wu,Lai-Chu; Zhao,Xi; Fehniger,Todd,A; Vij,Ravi; Byrd,John,C; Blum,William; Lee,L,James; Caligiuri,Michael,A; Bloomfield,Clara,D; Garzon,Ramiro; Marcucci,Guido. "Lenalidomide-mediated enhanced translation of C/EBP alpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia." BLOOD. Vol. 121, no. 1. (January 2013.): 159-169.

Mims,A; Walker,A,R; Huang,X; Sun,J; Wang,H; Santhanam,R; Dorrance,A,M; Walker,C; Hoellerbauer,P; Tarighat,S,S; Chan,K,K; Klisovic,R,B; Perrotti,D; Caligiuri,M,A; Byrd,J,C; Chen,C-S; Lee,L,James; Jacob,S; Mrozek,K; Bloomfield,C,D; Blum,W; Garzon,R; Schwind,S; Marcucci,G. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia." LEUKEMIA. Vol. 27, no. 4. (April 2013.): 871-878.

Huang,Xiaomeng; Schwind,Sebastian; Yu,Bo; Santhanam,Ramasamy; Wang,Hongyan; Hoellerbauer,Pia; Mims,Alice; Klisovic,Rebecca; Walker,Alison,R; Chan,Kenneth,K; Blum,William; Perrotti,Danilo; Byrd,John,C; Bloomfield,Clara,D; Caligiuri,Michael,A; Lee,Robert,J; Garzon,Ramiro; Muthusamy,Natarajan; Lee,Ly,James; Marcucci,Guido. "Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia." CLINICAL CANCER RESEARCH. Vol. 19, no. 9. (May 2013.): 2355-2367.

Wang,Hongyan; Chen,Ping; Wang,Jiang; Santhanam,Ramasamy; Aimiuwu,Josephine; Saradhi,U,VVijaya; Liu,Zhongfa; Schwind,Sebastian; Mims,Alice; Byrd,John,C; Grever,Michael,R; Villalona-Calero,Miguel,A; Klisovic,Rebecca; Walker,Alison; Garzon,Ramiro; Blum,William; Chan,Kenneth,K; Marcucci,Guido. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia." AAPS JOURNAL. Vol. 15, no. 1. (January 2013.): 242-249.

Schwind,Sebastian; Edwards,Colin,G; Nicolet,Deedra; Mrozek,Krzysztof; Maharry,Kati; Wu,Yue-Zhong; Paschka,Peter; Eisfeld,Ann-Kathrin; Hoellerbauer,Pia; Becker,Heiko; Metzeler,Klaus,H; Curfman,John; Kohlschmidt,Jessica; Prior,Thomas,W; Kolitz,Jonathan,E; Blum,William; Pettenati,Mark,J; Dal Cin,Paola; Carroll,Andrew,J; Caligiuri,Michael,A; Larson,Richard,A; Volinia,Stefano; Marcucci,Guido; Bloomfield,Clara,D. "inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations." BLOOD. Vol. 121, no. 2. (January 2013.): 385-391.

Walker,Alison,R; Klisovic,Rebecca; Johnston,Jeffrey,S; Jiang,Yao; Geyer,Susan; Kefauver,Cheryl; Binkley,Philip; Byrd,John,C; Grever,Michael,R; Garzon,Ramiro; Phelps,Mitch,A; Marcucci,Guido; Blum,Kristie,A; Blum,William. "Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia." LEUKEMIA & LYMPHOMA. Vol. 54, no. 9. (September 2013.): 1996-2002.

 

Reference Works

January 2001 Girgis M, Hallemeier C, Brown R, Khoury H, Zehnbauer B, Goodnough LT, Westervelt P, Vij R, Blum W, Lin H-S, DiPersio J, Adkins D."Low-dose (550 cGy), single exposure Total Body Irradiation (TBI) and Cyclophosphamide as conditioning for Unrelated Donor (URD) Bone Marrow Transplantation (BMT) results in reduced Non-Relapse Mortality (NRM) in comparison to standard TBI-based regimens" . : 671a
January 2001 Girgis M, Brown R, Khoury H, Hallemeier C, Zehnbauer B, Goodnough LT, Westervelt P, Vij R, Blum W, Lin HS, Dipersio J, Adkins D."Low-dose (550 cGy) single exposure Total Body Irradiation (TBI) and Cyclosphosphamide as conditioning for Unrelated Donor (URD) Bone Marrow Transplant (BMT) results in consistent donor cell engraftment without fatal Regimen-Related Toxicity (RROT)" .
January 2001 Shenoy S, Hayashi R, Goodnough LT, Khoury H, Brown R, Vij R, Blum W, DiPersio J, Adkins D.."Sustained improvement in post-transplant NK cell function following donor derived G-CSF mobilized granulocyte transfusion in recipients of allogeneic peripheral blood Stem Cell Transplants (SCT)." . : 59a
January 2001 Khoury H, Adkins D, Pence H, Shenoy S, Blum W, Westervelt P, Vij R, Brown R, Goodnough LT, DiPersio J.."Hydroxychloroquine for prevention of acute GVHD in unrelated donor (URD) transplantation: effect on chronic GVHD and long-term survival." . : 368b
January 2001 Omotoso O, Khoury H, Adkins D, Blum W, Iregui M, Westervelt P, Vij R, Brown R, Goodnough LT, DiPersio J.."Outcomes of stem cell transplant recipients requiring mechanical ventilation and cared for in the bone marrow transplant unit" . : 350b
January 2001 Brown R, Adkins D, Khoury H, Westervelt P, Goodnough LT, Vij R, Blum W, DiPersio J.."Mobilization of allogeneic PBSC with GM-CSF instead of G-CSF is associated with a reduced risk of acute Graft-Verses-Host Disease (GVHD)." . : 737a
January 2001 Blum W, Hallemeier C, Vij R, Shenoy S, Goodnough LT, Brown R, Khoury H, Westervelt P, DiPersio J, Adkins D.."Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: long-term follow-up." .
January 2001 Blum W, Brown R, Khoury H, Lin HS, Vij R, Oza Y, Schultz P, Rearden T, Willis R, Naughton M, Goodnough LT, Westervelt P, DiPersio J, Adkins D."Primary amyloidosis (AL) patients with significant organ dysfunction treated with conventional chemotherapy followed by single-dose Total Body Irradiation (TBI) and tolerance and efficacy." . : 684a
January 2002 Devine SM, Adkins DR, Khoury H, ViJ R, Goodnough LT, Graubert T, Tomasson M, Blum W. DiPersio JF, Brown RA.."Mobilization of donors with GM-CFS plus or GM-CSF alone results in significantly different graft composition comparted to G-CFS alone" . : abstract 3259
January 2002 Devine SM, Adkins DR, Khoury H, Vij R, Goodnough LT, Graubert T, Tomasson M, Blum W, DiPersio JF, Brown RA."Impact of GM-CFS Mobilization on the Composition of Donor Allografts and the Risk of Acute GVHD Following HLA-Matched Hematopoietic Cell Transplantation" .
January 2002 Hallemeier C, Girgis M, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine SM, Wehde M, Postma S, DiPersio J, Adkins D."Low-Dose (550 cGy), Single Exposure total body irradiation and cyclosphosphamide as conditioning for unrelated donor bone marrow transplantation for patients with acute myelogenous leukemia in complete remssion results in reduced non-relapse mortality and" .
January 2002 Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, DiPersio J, Adkins D."Low-Dose (550 cGy), Single-exposure Total Body Irradiation with Cyclophosphamide as Conditioning for 99 Patients Undergoing Unrelated Done Bone Marrow Transplantation Results in a Graft Failure Rate (7.1%) Comparable to that Observed with Standard TBI-bas" .
January 2002 Blum W, Girgis M, Hallemeier C, Vij R, Lin HS, Khoury H, Goodnough LT, Devine S, DiPersio J, Brown R, Adkins D."Outcomes for Patients with Non-Hodgkin's Lymphoma Following Donor Transplantation Using Low Dose, Single Exposure Total body Irradiation and Cyclophosphamide Conditioning: A Single Institution Experience" .
January 2003 Copelan E, Penza S, Lin T, Farag S, Blum W, Elder P, Ezzone S, Avalos B."Matched unrelated transplantation in older individuals" . : 480b
January 2003 Copelan E, Penza S, Lin T, Blum W, Farag S, Elder P, Avalos B."Association between regimen related toxicity and acute-graft-versus-host disease" .
January 2003 Copelan E, Penza S, Lin T, Blum W, Elder P, Ezzone S, Avalos B, Farag S."Results of Allogeneic Transplantation Using Fully Myeloablative Preparation in patients Who Are Candidates for Reduced Intensity Regimens" .
January 2003 Hallemeier C, Girgis M, Khoury H, Devine SM, Blum W, Vij R, Lin H, DiPersio J, Adkins D."Allogeneic stem cell transplantation of 45 patients with myelodysplastic syndrome conditioned with an intermediate-intensity regimen of single exposure 550 cGy total body irradiation and cyclophosphamide" .
January 2003 Hallemeier C, Girgis M, Khoury H, Devine SM, Blum W, Vij R, Lin H, DiPersio J, Adkins D."Similar outcomes in patients 50 years old and patients < 50 years old undergoing unrelated donor bone marrow transplantation following reduced intensity conditioning with single exposure (550cGy) total body irradiation and cyclophosphamide." .
January 2003 Blum W, Bolwell B, Farag S, Lin T, Avalos B, Penza S, Marcucci G, Byrd J, Kalaycio M, Sobecks R, Pohlman B, Brown S, Elder P, Copelan E."Only those refractory AML patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation." . : 448a
January 2004 Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd J, Elder P, Copelan E."Incidence of extramedullary relapse of acute myeloid leukemia following transplantation with busulfan-based conditioning regimens." . : abstract #5123
January 2004 Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rai KW, Pettenati MJ, Vardiman JW, Larson RA, Bloomfield CD, CALGB."Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t (6; 11) (q27; q23): Results from CALGB 8461" .
January 2004 Blum W, Blum K, Kefauver C, Moran M, Chan K, Byrd J, Cataland S, Grever M, Marcucci G.."Decitabine-induced differentiation syndrome in a patient with acute myeloid leukemia: A case report." . : abstract #4528
January 2004 Benson D, Elder P, Lin T, Blum W, Penza S, Avalos B, Byrd J, Copelan E, Farag, S."Single institution experience with two high-dose chemotherapy (HDC) conditioning regimens prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM)." . : abstract #5214
January 2004 Marcucci G, Stock W, Dai G, Liu S, Klisovic R, Klisovic M, Sher D, Huynh L, Frankel S, Blum W, Larson R, Grever M, Byrd J, Chan K."Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeloid leukemia (AML)" . : abstract #1170
January 2005 Klisovic R, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A Phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia: pharmacokinetics, pharmacodynamics and clinical activity" . : abstract #2790
January 2005 Klisovic R, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results." .
January 2005 Blum W, Mrozek, Maharry K, Raimondi SC, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD."Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes in adults with balanced chromosome aberrations of 11q23" . : 572s
January 2005 Blum W, Klisovic R, Liu S, Byrd JC, Liu Z, Chan KK, Kefauver C, Huynh L, Grever M, Marcucci G."Phase I study of low dose decitabine in patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity" . : abstract #1861
January 2006 Blum W, Marcucci G, Devine H, Klisovic R."Imatinib Mesylate-Induced Complete Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13" . : abstract #4414
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever MR, Marcucci G, Byrd JC."Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemia’s: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics." . : 18s
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas , Huynh, L, Liu S, Grever MR, Colevas AD, Marcucci G, Byrd JC."Updated Results of a Phase I Study of Flavopiridol in Acute Leukemia’s Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD)." .
November 2006 Sun J, Liu S, Yu J, Wei M, Mao C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic R, Perrotti D, Chen C, Blum W, Marcucci G."Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines" . : abstract #1988
January 2006 Marcucci G, Klisovic R, Wei W, Liu S, Paschka P, Huynh L., Zwiebel J. A., Byrd JC, M. R. Grever, K. Chan, Blum W."A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)." . : 18s 20
January 2006 Klisovic R, Blum W, Hackanson B, Kefauver C, Liu S, Liu Z, Chan KK, Plass C, Grever MR, Byrd JC, Marcucci G."Updated results of a phase I study of low dose decitabine and valproic acid in patients with acute myeloid leukemia: gene re expression, demethylation, and clinical response" . : 18S 20
January 2006 Ali NA, O'Brien JM, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow S, Byrd JC, Grever M."Hyperglycemia in patients with Acute Myeloid Leukemia is associated with increased hospital mortality" . : abstract #5515
January 2006 Liu S, Pang J, Yu J, Liu Z, Huynh L, Kearney J, Paschka P, Klisovic R, Baiocchi R, Blum W, Perrotti D, Marcucci G."Bortezomib-Induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-Positive Cells" . : abstract #4211
January 2007 Wetzler M, Stock W, Donohue K, Owzar K, Sher D, Hoke E, McCarty J, Blum W, Powell B, Bloomfield C, Linker C, Larson R."Autologous Stem Cell Transplantation (SCT) following sequential chemotherapy and Imatinib for adults with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) – CALGB study 10001" . : abstract #2869
January 2007 Marcucci G, Moser B, Blum W, Stock, Wetzler, Kolitz, Thakuri, Carter, Stuart, Larson."A phase III randomized trial of intensive induction and consolidation chemotherapy+ oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated actue myeloid leukemia patients >60 years old" .
January 2007 Andritsos A, Johnson AJ,Blum W, Kefauver C, Awan F, Smith L, Lapalombella R, Wang D, Knight R, Chen C, Byrd JC."Unacceptable toxicity of Lenalidomide when administered to CLL patients at higher doses." . : abstract #4727
November 2007 Garzon R, Liu S, Fabbri M, Liu Z, Pang J, Muthusamy N, Blum W, Chan K, Byrd JC, Croce C, Marcucci G.."MicroRNA (miRNA)-29b Targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML)." . : abstract #718
November 2007 Blum W, Klisovic R, Johnson A, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, Dalton J, Grever M, Marcucci G, Byrd JC."Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule" . : abstract #890
November 2007 Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin t, Andritsos L, Bechtel T, Blum K, Klisovic R, Devine S."High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditoning Regimen Incorporation Fludarabine, Busulfan, and Rabbit ATG" . : abstract # 5080
January 2008 Hamandani M, Blum W, Benson D, Blum K, Porcu P, Elder P, Krugh D, Bechtel T, Andritsos L, Garzon R, Penza S, Lin T, Devine S."Assessment of Rabbit Antithymocyte Globulin (rATG) dose-intensity in patients with hematological malignancies undergoing Allogeneic Stem Cell Transplantation (ASCT) following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATF (FBA)" San Fracisco.
January 2008 Hamadani M, Blum KA, Elder P, Lin TS, Porcu P, Hofmeister C, Blum W, Marcucci G, Benson D, Devine S."Allogeneic Stem Cell Transplantation for patients with chemo-refractory or progressive aggressive Non-Hodgkin's Lymphomas" San Francisco.
January 2008 Blum W, Klisovic R, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S, Grever M, Chan K, Villalona-Calero M, Byrd JD, Marcucci G."Preliminary results of a Phase II study of low dose Decitabine as a single agent in older patients (age >_ 60) with previously untreated Acute Myeloid Leukemia (AML)" San Francisco.
January 2008 Blum W, Andritsos L, Johnson AJ, Klisovic R, Kefauver C, Devine S, Marcucci G, Byrd JC."Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dos" .
January 2008 Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones JA, Blum W, Elder P, Lozanski G, Byrd JC, Devine S."Natural killer cell immune reconstruction predicts outcomes for patients with Chronic Lymphocytic Leukemia undergoing Allogeneic Stem Cell Transplantation" San Francisco.
January 2008 Andritsos L, Hamadani M, Heerema N, Benson D, Hofmeister C, Blum W, Flynn J, Jones JA, Elder P, Lin T, Lozanski G, Byrd JC, Devine S."Attainment of minimal residual disease negative state is crucial for successful outcome of reduced intensity conditioning Allogeneic Stem Cell Transplantation in advanced Chronic Lymphocytic Leukemia (CLL)" San Franciso.
December 2009 Maddocks K, Lapalombella R, Blum K, Blum W, Fischer B, Muthusamy N, Moran M, Holtzapfel D, Byrd JC, Johnson AJ, Andritsos L."Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia" . : abstract #3446
January 2009 Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf L, Humphries K, Grever M, Devine SM, Byrd JC, Marcucci G."Epigenetic targeting via transcriptional inhibition of DNA methyltransferase: a phase I study of bortezomib in combination with 5-azacytidine in adults with relapsed or refractory acute myeloid leukemia (AML)" . : abstract #2065
January 2009 Blum W, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-Calero M, Marcucci G."Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older" Orlando.
January 2009 Chandler JC, Klisovic KB, Phelps M, Walker A, Garzon R, Yan X, Schaaf L, Schwind S, Becker H, Liu S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W."Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia" . : abtract #841
December 2009 DiPersio J, Collins R, Blum W, Devetten M, Stiff P, Elias L, Reddy A, Smith J, Khoury HJ."Immune response in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase catalytic subunit hTERT" . : abstract #633
December 2009 Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic R, Garzon R, Grever M, Villalona-Calero M, Byrd JC, Chan K, Marcucci G."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine" . : abstract #3782
November 2009 Aimiuwu J, Chen P, Xie Z, Liu Z, Liu S, Klisovic R, Blum W, Marcucci G, Chan KK."Development and characterization of 5-Azacytidine resistance in human cancer cell lines" Los Angeles.
December 2010 Blum W, Klisovic RB, Garzon R, Walker A, Schwind S, Liu S, Schaaf L, Garr C, Devine SM, Grever MR, Byrd JC, Marcucci G."Phase I Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (MAL)" . : Abstract #3293
December 2010 Blum W, Donohue K, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W, Baer M, Kolitz JE, Wetzler M, Hoke E, Moser BK, Larson RA."Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy in Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study" . : Abstract #2176
December 2010 Attar EC, Donohue KA, Amrein PC, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum W, Booth A, Stone RM, Moser BK, Larson R."Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502" . : Abstract #331
December 2010 Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caliguri MA, Marcucci G, Bloomfield CD."Mutations in the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study" . : Abstract #98
December 2010 Khoury HJ, Collins RH, Blum W, Maness L, Stiff P, Kelsey SM, Reddy A, Smith JA, Dipersio JF."Prolonged Administration of the Telomerase Vaccine GRNVAC1 is Well Tolerated and Appears to be Associated with Favorable Outcomes in High-Risk Acute Myeloid Leukemia (AML)" . : Abstract #2190
November 2011 Walker A, Metzeler K, Geyer S, Becker H, Schwind S, Whitman S, Curfman J, Wu Y-Z, Perrotti D, Klisovic R, Garzon R, Blum W, and Marcucci G.". Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)" Washington. : 118:944
November 2011 Mendler J, Maharry K, Radmacher M, Mrózek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler K, Schwind S, Whitman S, Blum W, Powell B, Kolitz J, Carter T, Wetzler M, MooreJ, Carroll A, Baer M, Larson R, Caligiuri M, Marcucci G, and Bloomfield C."Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures" Washington.
November 2011 Lewis C, Heerema NA, Blum W, Whitman J, Hanna J."Culture fibroblasts to determine if abnormalities are constitutional or part of the patient’s disease state" n/a. : 37(3) 192
November 2011 Edwards C, Maharry K, Mrózek K, Schwind S, Paschka P, Nicolet D, Kohlschmidt J, Prior T, Wu Y-Z, Kolitz J, Blum W, Pettenati M, Dal Cin P, Carroll A, Caligiuri M, Larson R, Marcucci G, and Bloomfield C."Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)" Washington. : 118:2514

Presentations

"Treatment of AML : a comprehensive overview of AML pathophysiology, screening, and diagnostic procedures. Explain the mechanisms of action, side effects and plane in therapy of pharmacologic treatment modalities used in teh management of AML and outline practice guidlines for the management of AML." Columbus, OH, US|USA. (November 2005)

"Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene re expression, demethylation, and clinical response." Presented at 2006 American Society of Oncology Annual Meeting, Special Clinical Science Symposium on epigenetic therapy, Atlanta, GA, US|USA. (June 2006)

"Flavopiridol in acute leukemia; examples of collaborative use of PK/PD cores & protocol development." Presented at The Ohio State University Pediatric Oncology Program Retreat, Columbus, OH, US|USA. (December 2006)

"Epigenetic therapy in the treatment of myelodysplastic syndromes." Presented at Cancer Center Grand Rounds, Royal Oaks, MI, US|USA. (December 2006)

"Myelodysplastic syndrome; exciting new developments in hematology." Columbus, OH, US|USA. (May 2006)

"Acute Myeloid Leukemia and Myelodysplastic Syndrome, recognizing blood cancers in the family practice." Columbus, OH, US|USA. (May 2006)

"Acute Myeloid Leukemia, Recognizing blood cancer's in the family practice." Columbus, OH, US|USA. (October 2006)

"Treatment of acute progranulocytic leukemia." Presented at Oncology Nursing Society (ONS) Congress, Las Vegas, NV, US|USA. (April 2007)

"AML in the older adult: disease overview and current research." Presented at Oncology Nursing Society (ONS) Congress, Las Vegas, NV, US|USA. (April 2007)

"AML/MDS update; oncology and hematology 2007 Review and interpretation of the 2007 ASCO, ASH, AACR and other major international meetings." Columbus, OH, US|USA. (June 2007)

"Role of epigenetic therapy in AML." Presented at Chemotherapy Symposium XXV, New York, NY, US|USA. (November 2007)

"The use of hypomethylating agents in treating aggressive MDS." Indianapolis, IN, US|USA. (March 2007)

"A comprehensive overview of myelodysplastic syndrome pathophysiology, screening, and diagnostic procedures. Explain mechanisms of action, side effects, and place in therapy of pharmacologic treatment modalities used in the management of the myelodysplastic syndromes. Outline practice guidelines for the management of myelodysplastic syndromes." Presented at MDS Review, Columbus, OH, US|USA. (March 2007)

"Emerging therapies for MDS." Akron, OH, US|USA. (May 2007)

"Epigenetic therapy in AML: Histone deacetylase inhibitors." Presented at Clinical Advances in Epigenetic Therapy Conference, Charleston, SC, US|USA. (September 2007)

"Challenging cases in hematology, aggressive MDS." Presented at NMCR, Las Vegas, NV, US|USA. (September 2007)

"Diagnostic testing in acute leukemia's and other hematologic malignancies: What do I send this for?." Presented at Transplant Nursing Conference, Bone Marrow Transplant Tandem Meeting, Keystone, CO, US|USA. (February 2007)

"Decitabine, a new therapeutic option for MDS." Dayton, OH, US|USA. (July 2007)

"Translational oncology: pathways to future cancer therapies." Presented at NOCR Annual Conference, Las Vegas, NV, US|USA. (March 2008)

"Tanespimycin-Bortezomib phase I trial in leukemia." Presented at Proteasome Inhibitor Combination Trials with Targeted Agents Meeting - NCI, Bethesda, MD, US|USA. (April 2008)

"Bortezomib as an epigenetic targeting agent." Presented at Proteasome Inhibitor Combination Trials with Targeted Agents Meeting - NCI, Bethesda, MD, US|USA. (April 2008)

"Advances in management of myelodysplastic syndrome." Presented at Grand Rounds, Fort Wayne, IN, US|USA. (September 2008)

"CALGB 10503 Update and Future Plans." Presented at CALGB Leukemia Committee Meeting, . (January 2008)

"Myelodysplastic Syndromes: An Update from ASH." Columbus, OH, US|USA. (January 2008)

"Myelodysplasia." Presented at ASH Review, Columbus, OH, US|USA. (January 2008)

"Advances in Management of Myelodysplastic Syndrome." Presented at Grand Rounds, Bowling Green, KY, US|USA. (August 2008)

"Advances in the Management of Myelodysplastic Syndromes." Presented at MDS Grand Rounds, Zanesville, OH. (December 2008)

"Acute Leukemia." Presented at ASH Annual Conference Review, Columbus, OH. (January 2009)

"High-risk Myelodysplastic Syndromes." Presented at OptumHealth Education Program, Columbus, OH. (September 2009)

"Development of a new strategy for treatment of older AML patients." Presented at Leukemia Core Committee Meeting, Chicago, IL. (September 2009)

"CALGB 10503 Update and Future Plans." Presented at CALGB Leukemia Core Committee Meeting, Chicago, IL. (September 2009)

"Myelodysplastic Syndromes." Presented at OptumHealth Education Program, Lebanon, OH. (March 2009)

"How to get an R21 grant." Presented at ASCO Internation Meeting, Orlando, FL. (June 2009)

"Remission in older AML patients treated with a novel schedule of Decitabine: miR-29b as a potential predictive marker." Presented at OSUCCC Annual Scientifc Meeting, Columbus, OH. (February 2010)

"How much? How Frequent? How Long? A clinical guide to new therapies in MDS." Presented at 2010 ASH Annual Meeting, Orlando, FL. (December 2010)

"Acute Myeloid Leukemia - Therapy, excluding transplantation: Pediatric and adult AML therapy." Presented at 2010 ASH Annual Meeting, Orlando, FL. (December 2010)

"Phase I trial of decitabine and bortezomib in AML." Presented at Fall 2010 CTEP EDD Meeting, Bethesda, MD. (September 2010)

"Acute Leukemias." Presented at 2009 ASH Review, Columbus, OH. (January 2010)

"Advances in the management of high-risk AML." Presented at Tumor Board Conference, Atlanta, GA. (April 2010)

"R21 Grants, Perseverance, and Resubmission." Presented at Grant Writing Workshop I & II, Chicago, IL. (June 2010)

"Leukemia/Myeloma." Presented at 2010 ASCO Review, Columbus, OH. (June 2010)

"Leukemia, Myelodyspasia, and transplantation." Presented at ASCO Annual Conference, Chicago, IL. (June 2010)

"Myelodysplastic Syndromes." Presented at 2011 Highlights of ASH in North America, New York, NY. (February 2011)

"Myelodysplastic Syndromes." Presented at 2011 Highlights of ASH in North America, Vancouver, BC, CA|CAN. (January 2011)

"Blood disorders that cause cytopenias (DDF)." Presented at OSU MedNet 21 CME Webcast, Columbus, OH. (July 2011)

 

Professional Activities

2003 - present Spring Relay for Life Kick off Rally. Grove City, OH.
2003 - present Relay for LIfe (summer). American Cancer Society. Pickerington, OH.
2009 - present NCI Challenge Grants.
2010 - present Multidisciplinary Research Grant. State of North Carolina.
2007 Italian Association of Cancer Research.